Our Science – Roschke Website
Anna V. Roschke, Ph.D.
Selected Publications |
 |
| 1)
Cheng Y, Zhang Z, Keenan B, Roschke AV, Nakahara K, Aplan PD. Efficient repair of DNA double-strand breaks in malignant cells with structural instability. Mutat. Res. 683: 115-22, 2010. [Journal] |
|
| 2)
Roschke AV, Kirsch IR. Targeting karyotypic complexity and chromosomal instability of cancer cells. Curr Drug Targets. 11: 1341-50, 2010. [Journal] |
|
| 3)
Roschke AV, Glebov OK, Lababidi S, Gehlhaus KS, Weinstein JN, Kirsch IR. Chromosomal instability is associated with higher expression of genes implicated in epithelial-mesenchymal transition, cancer invasiveness, and metastasis and with lower expression of genes involved in cell cycle checkpoints, DNA repair, and chromatin maintenance. Neoplasia. 10: 1222-30, 2008. [Journal] |
|
| 4)
Gabrea A, Martelli ML, Qi Y, Roschke A, Barlogie B, Shaughnessy JD, Sawyer JR, Kuehl WM. Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Genes Chromosomes Cancer. 47: 573-90, 2008. [Journal] |
|
| 5)
Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, Dave SS, Tan B, Zhao H, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Campo E, Jaffe ES, Smeland EB, Fisher RI, Kuehl WM, Chan WC, Staudt LM. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J. Exp. Med. 204: 633-43, 2007. [Journal] |
|
| 6)
Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, Gwadry F, Kouros-Mehr H, Fridlyand J, Jain A, Collins C, Nishizuka S, Tonon G, Roschke A, Gehlhaus K, Kirsch I, Scudiero DA, Gray JW, Weinstein JN. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol. Cancer Ther. 5: 853-67, 2006. [Journal] |
|
| 7)
Wallqvist A, Huang R, Covell DG, Roschke AV, Gelhaus KS, Kirsch IR. Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells. Mol. Cancer Ther. 4: 1559-68, 2005. [Journal] |
|
| 8)
Roschke AV, Lababidi S, Tonon G, Gehlhaus KS, Bussey K, Weinstein JN, Kirsch IR. Karyotypic "state" as a potential determinant for anticancer drug discovery. Proc. Natl. Acad. Sci. U.S.A. 102: 2964-9, 2005. [Journal] |
|
| 9)
Roschke AV, Kirsch IR. Targeting cancer cells by exploiting karyotypic complexity and chromosomal instability. Cell Cycle. 4: 679-82, 2005. [Journal] |
|
| 10)
Reinhold WC, Kouros-Mehr H, Kohn KW, Maunakea AK, Lababidi S, Roschke A, Stover K, Alexander J, Pantazis P, Miller L, Liu E, Kirsch IR, Urasaki Y, Pommier Y, Weinstein JN. Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res. 63: 1000-11, 2003. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 5/16/2013.
